Arcturus Therapeutics (NASDAQ:ARCT) Upgraded to Hold at StockNews.com

Arcturus Therapeutics (NASDAQ:ARCTGet Rating) was upgraded by stock analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued on Monday.

Other equities research analysts also recently issued reports about the stock. Raymond James downgraded shares of Arcturus Therapeutics from a “market perform” rating to an “underperform” rating in a research note on Wednesday, August 10th. Wells Fargo & Company decreased their target price on Arcturus Therapeutics from $105.00 to $98.00 and set an “overweight” rating for the company in a report on Wednesday, August 10th. Barclays raised Arcturus Therapeutics from an “underweight” rating to an “equal weight” rating and boosted their price objective for the stock from $16.00 to $25.00 in a research report on Wednesday, November 2nd. Cantor Fitzgerald lifted their price target on shares of Arcturus Therapeutics from $39.00 to $44.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 2nd. Finally, Brookline Capital Management reissued a “buy” rating on shares of Arcturus Therapeutics in a research report on Wednesday, August 10th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $35.38.

Arcturus Therapeutics Stock Down 0.6 %

NASDAQ:ARCT opened at $22.82 on Monday. Arcturus Therapeutics has a 52 week low of $11.70 and a 52 week high of $48.75. The company has a quick ratio of 3.14, a current ratio of 3.14 and a debt-to-equity ratio of 0.21. The stock’s fifty day moving average is $16.04 and its two-hundred day moving average is $17.01. The stock has a market capitalization of $606.46 million, a price-to-earnings ratio of -3.63 and a beta of 2.51.

Arcturus Therapeutics (NASDAQ:ARCTGet Rating) last announced its earnings results on Tuesday, August 9th. The biotechnology company reported ($0.82) EPS for the quarter, beating analysts’ consensus estimates of ($1.90) by $1.08. The company had revenue of $27.09 million during the quarter, compared to analysts’ expectations of $3.33 million. Arcturus Therapeutics had a negative return on equity of 78.54% and a negative net margin of 407.91%. During the same period last year, the business posted ($2.07) EPS. Research analysts anticipate that Arcturus Therapeutics will post -6.56 EPS for the current year.

Institutional Investors Weigh In On Arcturus Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Federated Hermes Inc. raised its position in Arcturus Therapeutics by 1.8% in the 1st quarter. Federated Hermes Inc. now owns 3,761,900 shares of the biotechnology company’s stock valued at $101,421,000 after purchasing an additional 66,971 shares during the last quarter. State Street Corp raised its holdings in shares of Arcturus Therapeutics by 56.5% in the first quarter. State Street Corp now owns 3,217,957 shares of the biotechnology company’s stock valued at $86,756,000 after buying an additional 1,161,883 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. raised its holdings in shares of Arcturus Therapeutics by 1.6% in the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,459,415 shares of the biotechnology company’s stock valued at $21,629,000 after buying an additional 23,221 shares during the last quarter. Nikko Asset Management Americas Inc. boosted its stake in shares of Arcturus Therapeutics by 2.4% during the second quarter. Nikko Asset Management Americas Inc. now owns 1,436,194 shares of the biotechnology company’s stock worth $17,952,000 after buying an additional 34,116 shares during the period. Finally, Vanguard Group Inc. increased its position in Arcturus Therapeutics by 0.5% in the 1st quarter. Vanguard Group Inc. now owns 1,153,513 shares of the biotechnology company’s stock valued at $31,099,000 after acquiring an additional 6,291 shares during the period. Hedge funds and other institutional investors own 83.55% of the company’s stock.

Arcturus Therapeutics Company Profile

(Get Rating)

Arcturus Therapeutics Holdings Inc, an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU.

Further Reading

Analyst Recommendations for Arcturus Therapeutics (NASDAQ:ARCT)

Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.